Literature DB >> 428184

A scale for assessing the severity of diseases and adverse drug reactions. Application to drug benefit and risk.

R J Tallarida, R B Murray, C Eiben.   

Abstract

Physicians were interviewed to assess their willingness to risk adverse drug reactions among patients. These untoward reactions were ranked according to severity and weighted against the primary illness being treated. A specially designed questionnaire in the form of a matrix was used. Severity was divided into seven classes denoted by progressively increasing numerical scores, W1 to W7, whose values could be calculated from analysis of the completed questionnaires. The questionnaires presented several cases, in each of which an illness of specified severity was to be treated with a drug whose untoward reactions differ in severity from that of the primary illness. Each case involved a different permutation of the severities. Analysis of the completed questionnaires yielded the mean values of the scores which were found to range from W1 = 1.00 (the mildest case) to W7 = 817 (the most serious case). It is our opinion that this type of scale is preferable to nonnumerical descriptions of severity such as "mild" or "serious," since, when combined with data on frequency of occurrence, a numerical scale permits a determination of expectation of both benefit and risk.

Entities:  

Mesh:

Year:  1979        PMID: 428184     DOI: 10.1002/cpt1979254381

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Benefit-risk analysis : a brief review and proposed quantitative approaches.

Authors:  William L Holden
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Assessment of adverse drug reactions in psychiatric hospitals.

Authors:  R Grohmann; H Hippius; B Müller-Oerlinghausen; E Rüther; J Scherer; L G Schmidt; A Strauss; B Wolf
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  M Jawad; R Schoop; A Suter; P Klein; R Eccles
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-16       Impact factor: 2.629

4.  Risk characterization framework for noncancer end points.

Authors:  T K Pierson; R G Hetes; D F Naugle
Journal:  Environ Health Perspect       Date:  1991-11       Impact factor: 9.031

5.  Joint distribution approaches to simultaneously quantifying benefit and risk.

Authors:  Michele L Shaffer; Kristi L Watterberg
Journal:  BMC Med Res Methodol       Date:  2006-10-12       Impact factor: 4.615

6.  Ranking adverse drug reactions with crowdsourcing.

Authors:  Assaf Gottlieb; Robert Hoehndorf; Michel Dumontier; Russ B Altman
Journal:  J Med Internet Res       Date:  2015-03-23       Impact factor: 5.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.